Result of AGM ASTRAZENECA PLC - ANNUAL GENERAL MEETING 2015

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 24, 2015 at 1:00 PM

Result of AGM

ASTRAZENECA PLC - ANNUAL GENERAL MEETING 2015 Results of Annual General Meeting held on 24 April 2015 AstraZeneca PLC announced the results of the voting at its Annual General Meeting today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 12 were passed as special resolutions. RESOLUTION VOTES FOR % OF VOTES % OF VOTES CAST TOTAL VOTES VOTES AGAINST VOTES IN TOTAL VOTES WITHHELD CAST CAST CAST AS A % OF ISSUED SHARE CAPITAL 1 To receive 877,576,463 99.67 2,921,581 0.33 880,498,044 69.68% 10,675,935 the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2014 2 To confirm 886,527,613 99.66 2,986,602 0.34 889,514,215 70.40% 1,659,763 dividends 3 To re 876,751,815 98.61 12,397,571 1.39 889,149,386 70.37% 2,024,593 -appoint KPMG LLP, London as Auditor 4 To authorise 887,495,062 99.82 1,629,520 0.18 889,124,582 70.37% 2,049,398 the Directors to agree the remuneration of the Auditor 5a To re-elect 851,461,560 95.76 37,705,142 4.24 889,166,702 70.37% 2,007,277 Leif Johansson as a Director 5b To re-elect 888,590,119 99.95 426,241 0.05 889,016,360 70.36% 2,157,620 Pascal Soriot as a Director 5c To re-elect 885,602,969 99.62 3,374,856 0.38 888,977,825 70.36% 2,196,155 Marc Dunoyer as a Director 5d To elect 888,638,513 99.96 351,446 0.04 888,989,959 70.36% 2,184,021 Cori Bargmann as a Director 5e To re-elect 888,552,754 99.95 465,106 0.05 889,017,860 70.36% 2,156,120 Geneviève Berger as a Director 5f To re-elect 880,639,560 99.88 1,091,107 0.12 881,730,667 69.78% 9,443,312 Bruce Burlington as a Director 5g To re-elect 888,587,093 99.95 465,731 0.05 889,052,824 70.36% 2,121,156 Ann Cairns as a Director 5h To re-elect 876,994,757 99.46 4,732,631 0.54 881,727,388 69.78% 9,445,684 Graham Chipchase as a Director 5i To re-elect 880,585,784 99.87 1,137,760 0.13 881,723,544 69.78% 9,450,753 Jean -Philippe Courtois as a Director 5j To re-elect 855,335,488 99.27 6,300,712 0.73 861,636,200 68.19% 29,537,348 Rudy Markham as a Director 5k To re-elect 888,387,120 99.93 582,556 0.07 888,969,676 70.36% 2,204,192 Shriti Vadera as a Director 5l To re-elect 846,091,821 98.19 15,599,701 1.81 861,691,522 68.20% 29,482,025 Marcus Wallenberg as a Director 6 To approve 739,049,685 84.11 139,601,566 15.89 878,651,251 69.54% 12,522,725 the Annual Report on Remuneration for the year ended 31 December 2014 7 To authorise 859,081,444 97.36 23,307,997 2.64 882,389,441 69.83% 8,784,535 limited EU political donations 8 To authorise 808,454,239 91.14 78,551,101 8.86 887,005,340 70.20% 4,168,208 the Directors to allot shares 9 To authorise 875,263,416 98.61 12,347,679 1.39 887,611,095 70.25% 3,562,455 the Directors to disapply pre -emption rights 10 To authorise 876,130,644 98.54 13,023,264 1.46 889,153,908 70.37% 2,019,960 the Company to purchase its own shares 11 To reduce 778,280,838 87.53 110,881,255 12.47 889,162,093 70.37% 2,011,885 the notice period for general meetings 12 To adopt new 886,456,629 99.90 900,552 0.10 887,357,181 70.23% 3,813,971 Articles of Association Issued capital As at 22 April 2015, the number of issued shares of the Company was 1,263,544,938, ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held. A C N Kemp Company Secretary 24 April 2015

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

CapCut's Role in AI-Assisted Small Biz Marketing

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Apalutamide Boosts Outlook for Prostate Cancer Treatment

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

TORRAS Cases Balance Protection with Slim Design for 2026

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Swanson Nexus Pro Launch: Boost for Dietitians

By Lucas Young Updated Oct 24, 2026 Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Innovent's IBI3001 Shows Promise in Phase 1 Trials

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

World Young Scientist Summit 2026 in Wenzhou Kicks Off

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...